Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Highlights

Highlights In This Issue September 2019 Volume 4, Number 9 JAMA Cardiology Pages 837-956 Research Opinion Editor's Note Simvastatin-Ezetimibe vs Simvastatin in Older Patients 846 844 Improving Quality for All Patients Limitedevidenceexistsregardingthebenefitsandhazardsofintensivelipid-loweringtherapy With Aortic Stenosis among patients 75 years or older. In a prespecified secondary analysis of the IMPROVE-IT PT O’Gara and Coauthors trial, Bach and coauthors investigated outcomes after acute coronary syndrome in 18 144 873 Regional Differences in Secondary patients stratified by age. During a median follow-up of 6 years, treatment with a combi- Prevention Therapy—Geography nation of simvastatin and ezetimibe resulted in lower rates of major cardiovascular events Should Not Be Destiny AM Navar and GC Fonarow than treatment with simvastatin and placebo, with the greatest absolute risk reduction of 8.7% for patients 75 years or older. Rates of adverse events did not differ between those 927 Risk Prediction Model in Children With Hypertrophic Cardiomyopathy: receiving simvastatin and ezetimibe vs simvastatin and placebo among younger or older A Work in Progress patients. In an Invited Commentary, Gotto notes that these data address an important evi- RO Bonow and EM McNally dence gap regarding efficacy and safety of more intensive lipid lowering in elderly pa- tients. Clinical Review http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Cardiology American Medical Association

Highlights

JAMA Cardiology , Volume 4 (9) – Sep 1, 2019

Highlights

Abstract

In This Issue September 2019 Volume 4, Number 9 JAMA Cardiology Pages 837-956 Research Opinion Editor's Note Simvastatin-Ezetimibe vs Simvastatin in Older Patients 846 844 Improving Quality for All Patients Limitedevidenceexistsregardingthebenefitsandhazardsofintensivelipid-loweringtherapy With Aortic Stenosis among patients 75 years or older. In a prespecified secondary analysis of the IMPROVE-IT PT O’Gara and Coauthors trial, Bach and coauthors investigated outcomes after acute...
Loading next page...
 
/lp/american-medical-association/highlights-g4X47l0Q4Y
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2380-6583
eISSN
2380-6591
DOI
10.1001/jamacardio.2018.3215
Publisher site
See Article on Publisher Site

Abstract

In This Issue September 2019 Volume 4, Number 9 JAMA Cardiology Pages 837-956 Research Opinion Editor's Note Simvastatin-Ezetimibe vs Simvastatin in Older Patients 846 844 Improving Quality for All Patients Limitedevidenceexistsregardingthebenefitsandhazardsofintensivelipid-loweringtherapy With Aortic Stenosis among patients 75 years or older. In a prespecified secondary analysis of the IMPROVE-IT PT O’Gara and Coauthors trial, Bach and coauthors investigated outcomes after acute coronary syndrome in 18 144 873 Regional Differences in Secondary patients stratified by age. During a median follow-up of 6 years, treatment with a combi- Prevention Therapy—Geography nation of simvastatin and ezetimibe resulted in lower rates of major cardiovascular events Should Not Be Destiny AM Navar and GC Fonarow than treatment with simvastatin and placebo, with the greatest absolute risk reduction of 8.7% for patients 75 years or older. Rates of adverse events did not differ between those 927 Risk Prediction Model in Children With Hypertrophic Cardiomyopathy: receiving simvastatin and ezetimibe vs simvastatin and placebo among younger or older A Work in Progress patients. In an Invited Commentary, Gotto notes that these data address an important evi- RO Bonow and EM McNally dence gap regarding efficacy and safety of more intensive lipid lowering in elderly pa- tients. Clinical Review

Journal

JAMA CardiologyAmerican Medical Association

Published: Sep 1, 2019

There are no references for this article.